Archive for 'Tag Archives: 'Cell therapy''
Updating on the February 15th post, some exciting new developments have recently occurred that further strengthen Bone Therapeutics’ cell product manufacturing capabilities. Following a successful Series D fundraising round, Bone Therapeutics, alongside the Walloon Region and private [...]
Bone Therapeutics completes a €7.7 Million Series D Fundraising round to further advance ongoing PREOB® Phase III clinical trials
Following the approval of the pivotal phase III osteonecrosis trial of PREOB® last November (posted Nov. 9, 2012), Bone Therapeutics has just completed a €7.7 million Series D fundraising round. Of the raised funds, €6.1 million were [...]
Bone Therapeutics gets approval for pivotal phase III osteonecrosis trial in Europe and treats first patients with their Advanced Therapy Medicinal Product PREOB®
After receiving clearance from the competent authorities in Europe for its phase III pivotal osteonecrosis* trial with their second generation Advanced Therapy Medicinal Product (ATMP), PREOB®, bone regenerative medicine company Bone Therapeutics recently announced that their [...]
100th spin-off of the University of Liège, SYNOLYNE SA (Liège, Belgium), develops patented chitosan-based hydrogel to wipe out arthritis.
SYNOLYNE SA, the new spin-off of Liège University and spin-out of Kitozyme SA, is specialized in the research, development and marketing of a chitosan-based hydrogel with mechanical and biological properties designed to protect the cartilage and [...]
Cardio3 BioSciences, a leader in discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases announced today, that it has signed a Letter of Intent with Advanced Technology Materials, Inc. (“ATMI”), a [...]
MaStherCell incorporation : a step forward to industrialization of cell therapy in Europe Gosselies, Belgium, November 4, 2011 : Boosted by the Wallonia government authorities and Biowin, MaStherCell , an innovative cGMP contract manufacturing platform, just [...]